National Institutes of Health (NIH)

PAR-21-339: Limited Competition: NCATS Clinical and Translational Science Award (CTSA) Program Research Education Grants Programs (R25 – Clinical Trial Not Allowed)

Slots: 1. NCATS solicits the submission of one set of companion applications. With this solicitation for the R25 application, a separate, companion FOA solicits applications for a required UM1 (PAR-21-293: Clinical and Translational Science Award). The UM1 and initial R25 applications must be submitted concurrently; an R25 application without the required companion UM1 application will not be reviewed. The R25 application will only be awarded if the UM1 application is awarded. Resubmission of an R25 without the required UM1 will be allowed only if the UM1 application is awarded. The sponsoring institution must assure support for the proposed program. Appropriate institutional commitment to the program includes the provision of adequate staff, facilities, and educational resources that can contribute to the planned program

Deadlines

Internal Deadline: October 22, 2021, 5pm PT

LOI: 30 days prior

External Deadline: January 26, 2022

Recurring Future Deadlines: May 13, 2022; September 16, 2022; January 13, 2023; May 12, 2023; September 15, 2023; January 12, 2024; May 17, 2024; September 13, 2024

Award Information

Award Type: Grant

Estimated Number of Awards: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Anticipated Award Amount: The maximum budget is $100,000 direct costs/year. The budget request for a given application needs to be adequately justified and reflect the actual needs of the proposed project. Yearly fluctuations in the project workload should be reflected in the requested budget.

Who May Serve as PI: The PD/PI should be an established investigator in the scientific area in which the application is targeted and capable of providing both administrative and scientific leadership to the development and implementation of the proposed program. The PD/PI will be expected to monitor and assess the program and submit all documents and reports as required.

The UM1 PD(s)/PI(s) may not be a PD(s)/PI(s) on the R25 award.

Link to Award: https://grants.nih.gov/grants/guide/pa-files/PAR-21-339.html

Process for Limited Submissions

PIs must submit their application as a Limited Submission through the Office of Research Application Portal: https://orif.usc.edu/oor-portal/.

Materials to submit include:

(1) Single Page Proposal Summary (0.5” margins; single-spaced; font type: Arial, Helvetica, or Georgia typeface; font size: 11 pt). Page limit includes references and illustrations. Pages that exceed the 1-page limit will be excluded from review.
(2) CV – (5 pages maximum)

Note: The portal requires information about the PIs and Co-PIs in addition to department and contact information, including the 10-digit USC ID#, Gender, and Ethnicity. Please have this material prepared before beginning this application.

Purpose

The overarching goal of this R25 program is to provide support to recipients of Clinical and Translational Science Awards (CTSA) for research experiencess that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish this over-arching goal, this FOA will support creative educational activities with a primary focus on:

Research Experiences:
- Research experiences are expected to be relevant to NCATS’ mission of studying translation on a system-wide level, agnostic to a specific disease, to better understand the scientific and operational principles underlying each step of the translational process. The goal is not to focus on specific diseases, but on what is common among them and the translational science process. Examples of research experiences appropriate for career levels include, but are not limited to:
  - Undergraduates: to provide hands-on exposure to research that reinforces their interest in clinical and translational science and/or prepares them for graduate school matriculation and/or careers in clinical and translational science for graduate and medical, dental, nursing and other health professional students.
  - Postdoctoral Fellows and Medical Residents: to extend their skills, experiences, and knowledge base in order to engage in clinical and translational science research activities.
  - Junior Faculty: to enhance their research skills, experiences, and knowledge base relative to clinical and translational science by working with faculty members at a partnering institution.
Proposed research experiences should involve an innovative approach to provide hands-on exposure to clinical and translational science research in a laboratory or a field setting for a full-time (40 hours per week) period of 10 to 15 weeks in order to stimulate the interest and advance the knowledge base of participants to consider further education and training for future careers as clinical and translational science researchers. The proposed programs should provide research experiences that are not available through formal NIH training mechanisms.R25 programs that propose at least 10 weeks, but fewer than 15 weeks, of full-time research experiences are allowed to request continued part-time support for the participants to work on their research projects, up to the equivalent of 15 weeks of full-time participation, as long as the entire research experience is completed within a 12-month period. Successful participants may be appointed for additional periods of short-term research experiences.

Research education programs may complement ongoing research training and education occurring at the applicant institution, but the proposed educational experiences must be distinct from those training and education programs currently receiving Federal support. R25 programs may augment institutional research training programs (e.g., T32, T90) but cannot be used to replace or circumvent Ruth L. Kirschstein National Research Service Award (NRSA) programs.

Budgetary Requirements: This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.

Visit our Institutionally Limited Submission webpage for more updates and other announcements.

RFA-DK-21-024: Pediatric Centers of Excellence in Nephrology (P50 Clinical Trial Optional)

Slots: 1

Deadlines

Internal Deadline: October 1, 2021, 5pm PT

LOI: October 18, 2021

External Deadline: November 18, 2021

Award Information

Award Type: Grant

Estimated Number of Awards: 3

Anticipated Award Amount: $2.63 million

Who May Serve as PI: The PCEN Director must be an established investigator with demonstrated research accomplishments and prior success in obtaining external funding.

Link to Award: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-024.html

Process for Limited Submissions

PIs must submit their application as a Limited Submission through the Office of Research Application Portal: https://orif.usc.edu/oor-portal/.

Materials to submit include:

(1) Single Page Proposal Summary (0.5” margins; single-spaced; font type: Arial, Helvetica, or Georgia typeface; font size: 11 pt). Page limit includes references and illustrations. Pages that exceed the 1-page limit will be excluded from review.
(2) CV – (5 pages maximum)

Purpose

The goals of the PCEN program are: 1. to attract new scientific expertise to the study of human pediatric renal physiology, kidney development, and pediatric kidney disorders; 2. to encourage multidisciplinary research in these areas; and 3. to develop the pediatric nephrology research community through a national research symposium, broad sharing of research resources, and a national Pilot and Feasibility grant program. These efforts are expected to lead to innovative approaches to study kidney disease in children and the eventual submission of substantial, competitive, investigator–initiated research applications. The PCEN will complement the O’Brien Kidney and Urological Research Centers and are expected to leverage existing institutional resources which may include Clinical Translational Science Awards, Institutional Network Awards for Promoting Kidney, Urologic, and Hematologic Research Training (U2C/TL1), and other KUH-funded consortia. It is anticipated that collaboration will occur among individuals in the clinical and basic sciences, including cell biology, molecular biology, immunology, genetics, epidemiology, biochemistry, physiology and pathology. Resources and studies that foster new approaches into the causes, early diagnoses and treatments, and where possible, prevention of these diseases and disorders are appropriate.

Each Center within the PCEN program will be thematically distinct, yet complementary to the national network of PCEN. The Centers will jointly arrange and sponsor a yearly, open, broadly advertised, scientific symposium featuring the research projects and biomedical cores at each site in the Bethesda MD/Washington DC area. Junior faculty will be particularly encouraged to present their work. Pilot and Feasibility awardees will present the results of their funded projects. (Further details provided below under Educational Enrichment activities).

The Pilot and Feasibility project application processes will be coordinated between Centers to avoid unnecessary duplication or conflicts and to attract and support the best people and ideas to further pediatric kidney research. (Further details provided below in section Pilot and Feasibility Program).

To promote collaboration, the PIs/PDs of each of the PCEN will have conference calls at least quarterly, joined by NIDDK program staff. It is anticipated these conference calls will include planning for the yearly open scientific meeting, coordination of widely publicized announcements and NIH-style reviews of Pilot and Feasibility project applications, and should include sharing of progress on research projects.

Budgetary Requirements: This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.

Visit our Institutionally Limited Submission webpage for more updates and other announcements.

RFA-DK-21-019: National Program for the Career Development Of Physician Scientists in Diabetes Research (Diabetes – Docs) (K12 Clinical Trial Optional)

Slots: 1

Deadlines

Internal Deadline: October 15, 2021, 5pm PT

LOI: N/A

External Deadline: November 18, 2021

Award Information

Award Type: Grant

Estimated Number of Awards: 1

Anticipated Award Amount: $2 million

Who May Serve as PI: The PD/PI or PD/PI(s) should be leader(s) in type 1 diabetes research with available effort and experience leading successful career development programs. The Program should include appropriate expertise to provide leadership for the career development of physician-scientists in type 1 diabetes research but may include expertise in type 2 diabetes research.

Link to Award: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-019.html

Process for Limited Submissions

PIs must submit their application as a Limited Submission through the Office of Research Application Portal: https://orif.usc.edu/oor-portal/.

Materials to submit include:

(1) Single Page Proposal Summary (0.5” margins; single-spaced; font type: Arial, Helvetica, or Georgia typeface; font size: 11 pt). Page limit includes references and illustrations. Pages that exceed the 1-page limit will be excluded from review.
(2) CV – (5 pages maximum)

Purpose

The purpose of the Diabetes-Docs Program is to support the career development of physicians committed to a career in diabetes research. The program is intended to remedy the dearth of pediatric endocrinologists and physicians from other specialties conducting innovative research into the causes and consequences of diabetes. Diabetes-Docs will be a single national program, implemented by one or more PD/PIs, together with an advisory committee composed of basic and clinical investigators who have a strong record of funded research and successful training of physician-scientists. Although there will be one national administrative center awardee, scholars are expected to be appointed and supported at their home institutions around the country. The program will have a focus on Type 1 Diabetes (T1D) research, with the major funding from the Statutory Special Diabetes Program https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/type-1-diabetes-special-statutory-funding-program/about-special-diabetes-program. Starting in the second year, the program will expand to support the career development of physicians whose research focuses on innovative projects in type 2 diabetes. The program is expected to deliver on goals to increase the diversity of physician scientists with independent research careers in the mission of NIDDK https://www.niddk.nih.gov/research-funding/research-programs#diabetes.

This Funding Opportunity Announcement (FOA) allows appointment of Scholars (K12) proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

Budgetary Requirements: This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.

Visit our Institutionally Limited Submission webpage for more updates and other announcements.

PAR-20-297: NIOSH Centers of Excellence for Total Worker Health® (U19)

Slots: 1

Deadlines

Internal Deadline: Contact ORIF if interested.

LOI: 30 days prior

External Deadline: October 29, 2021

Recurring Deadlines: October 28, 2022; October 30, 2023

Award Information

Estimated Number of Awards: 8

Estimated Total Funding: $11.2 million

Who May Serve as PI: Standard NIH requirements.

Link to Award: https://grants.nih.gov/grants/guide/pa-files/PAR-20-297.html

Process for Limited Submissions

PIs must submit their application as a Limited Submission through the Office of Research Application Portal: https://orif.usc.edu/oor-portal/.

Materials to submit include:

(1) Single Page Proposal Summary (0.5” margins; single-spaced; font type: Arial, Helvetica, or Georgia typeface; font size: 11 pt). Page limit includes references and illustrations. Pages that exceed the 1-page limit will be excluded from review.
(2) CV – (5 pages maximum)

Purpose

The National Institute for Occupational Safety and Health’s (NIOSH) TWH Program builds on four decades of scientific knowledge through the recognition that work is a social determinant of health; job-related factors such as wages, hours of work, workload and stress levels, interactions with coworkers and supervisors, access to paid leave, and health-promoting workplaces all can have an important impact on the well-being of workers, their families, and their communities. TWH is defined as policies, programs and practices that integrate protection from work-related safety and health hazards with promotion of injury and illness prevention efforts to advance worker well-being. This approach prioritizes a hazard-free work environment for all workers and comprehensively integrates workplace systems relevant to the control of hazards and exposures, organization of work, compensation and benefits, work-life integration/management, and organizational change management. The NIOSH TWH program supports ground-breaking research and practical applications that address the implications of today’s changing workplace and responds to demands for information and practical solutions to the health, safety, and well-being challenges that workers face.

Opioid and Other Substance Use Disorders in the Workplace
TWH Outreach, Education, and Training
Measuring Worker Well-Being
Future of Work
Healthy Work Design and Well-Being
Workplace Mental Health and Worker Well-Being

Visit our Institutionally Limited Submission webpage for more updates and other announcements.

RFA-DK-21-022: NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) Genetic Research Centers (GRCs) (U01 Clinical Trial Optional)

Slots: 1

Deadlines

Internal Deadline: October 8, 2021, 5pm PT

LOI: November 21, 2021

External Deadline: December 21, 2021

Award Information

Award Type: Cooperative Agreement

Estimated Number of Awards: NIDDK intends to commit $3,800,000 in FY 2022 to fund up to 7 awards.

Budget Info: Application budgets are limited to $375,000 direct costs per year.

Who May Serve as PI: Standard NIH requirements.

Link to Award: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-022.html

Process for Limited Submissions

PIs must submit their application as a Limited Submission through the Office of Research Application Portal: https://orif.usc.edu/oor-portal/.

Materials to submit include:

(1) Single Page Proposal Summary (0.5” margins; single-spaced; font type: Arial, Helvetica, or Georgia typeface; font size: 11 pt). Page limit includes references and illustrations. Pages that exceed the 1-page limit will be excluded from review.
(2) CV – (5 pages maximum)

Purpose

This Funding Opportunity Announcement (FOA), together with the companion FOA, RFA DK-21-502, invites applications to renew the NIDDK IBDGC to address three main research objectives: 1) to further characterize the genetic architecture of IBD phenotypes within populations currently underrepresented in IBD genomic research, integrating genetic and environmental predictors in risk models; 2) to identify the causal genetic variants and the genes, proteins and pathways they act upon within susceptibility loci for IBD phenotypes; and 3) to elucidate the biological mechanisms by which risk-associated and protective variants influence the pathophysiology of IBD and its clinically important sub-phenotypes and outcomes. The long-range goal of the research to be carried out by the IBDGC is the enhancement of our understanding of the pathophysiologic mechanisms of IBD in order to improve patient outcomes.

Identification of causal variants and of the genes they act upon can be accomplished via fine-mapping techniques involving high-density genotyping and exome and whole genome sequencing in large numbers of subjects from populations of diverse ancestry, integration of other molecular and regulatory datasets measured in patient samples and/or available via public databases, and screening and functional testing of candidate variants in laboratory-based assays and model systems. The IBDGC is expected to continue to apply current versions of these approaches to characterize more of the previously identified IBD loci, with particular attention to representing genetic heterogeneity and diverse ancestries in all methodological approaches. The IBDGC may also draw on the rich clinical datasets available via electronic health record (EHR) databases and associated biobanks to expand and characterize the IBD phenome, incorporate pharmacogenomic analyses, and identify new important phenotypes for analysis. In view of the central (but yet to be fully elucidated) role of the intestinal microbiota in the pathophysiology of IBD, the IBDGC may also continue analyses of the composition and activity of the intestinal microbiome, and integrate these results with other environmental exposures and risk factors, and with host genetics. Systems biology approaches and longitudinal studies will be needed to integrate genetic and multi-omic datasets along with pharmacogenetic and environmental exposure data to create and refine risk models for multiple IBD phenotypes and clinical outcomes.

Functional screening of candidate genes and variants and biological perturbation studies in a variety of experimental systems may be required to identify causal variants and to elucidate the mechanisms by which they act to influence IBD pathophysiology. Functional and mechanistic studies may employ any of a wide variety of assay platforms and model systems (e.g., cultured cells, organoids, zebrafish, mice) to investigate function in physiological domains relevant to IBD (e.g., gut barrier function, mucosal immunity). Investigators may culture cells from patients carrying variants of interest and generate organoids from them; such patient-derived models should be representative of the ancestral diversity of IBD patients. Alternatively, investigators may introduce mutations of interest into cell lines or model organisms via genome editing methods. These experimental systems and models may be used to test the effects of potential therapeutics suggested by the functional impacts of the genetic variants characterized.

Visit our Institutionally Limited Submission webpage for more updates and other announcements.

RFA-DK-21-026: Silvio O. Conte Digestive Diseases Research Core Centers (P30 Clinical Trial Optional)

Slots: 1

Deadlines

Internal Deadline: November 12, 2021, 5pm PT

LOI: 30 days prior

External Deadline: February 17, 2022

Award Information

Award Type: Grant

Estimated Number of Awards: NIDDK intends to commit $2.4 million in FY 2023 to fund 2 awards and $3.6 million in FY 2024 to fund 3 awards.

Budget Info: Application budgets are limited to $750,000 in direct costs per year and need to reflect the actual needs of the proposed Center.

Who May Serve as PI: Standard NIH requirements.

Link to Award: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-21-026.html

Process for Limited Submissions

PIs must submit their application as a Limited Submission through the Office of Research Application Portal: https://orif.usc.edu/oor-portal/.

Materials to submit include:

(1) Single Page Proposal Summary (0.5” margins; single-spaced; font type: Arial, Helvetica, or Georgia typeface; font size: 11 pt). Page limit includes references and illustrations. Pages that exceed the 1-page limit will be excluded from review.
(2) CV – (5 pages maximum)

Purpose

The objective of the Silvio O. Conte Digestive Diseases Research Core Centers (DDRCCs) is to bring together, on a cooperative basis, basic and clinical investigators to enhance the effectiveness of their research related to digestive and/or liver diseases and their complications. DDRCCs are meant to improve communication among investigators and to integrate, coordinate, and foster interdisciplinary research involving the etiology, treatment, and prevention of digestive and/or liver diseases. To accomplish this, the DDRCC supports a group of established investigators actively conducting programs of important, high-quality research that relates to a common theme in digestive diseases or liver diseases research. Thus, the purpose of a DDRCC is to provide the capability for accomplishments greater than those that would be possible by individual research project grant support alone. Applicants should consult NIDDK staff concerning plans for the development of the DDRCC and the organization of the application.

Visit our Institutionally Limited Submission webpage for more updates and other announcements.